Alnylam Pharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported revenue was USD 494.33 million compared to USD 319.29 million a year ago. Net loss was USD 65.94 million compared to USD 174.1 million a year ago.

Basic loss per share from continuing operations was USD 0.52 compared to USD 1.4 a year ago.